|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 178.75 USD | -1.94% |
|
-3.87% | +94.44% |
| 13/06 | AstraZeneca says Truqap combination approved in US for prostate cancer | AN |
| 13/06 | AstraZeneca Says FDA Approves Truqap Combination for PTEN-Deficient Prostate Cancer | MT |
| Market Cap | 28TCr 24TCr 22TCr 21TCr 39TCr 26,63900Cr 40TCr 2,63400Cr 1,02700Cr 12,96600Cr 1,05200Cr 1,02900Cr 44,89500Cr | P/E Ratio 2026 * |
22.8x | P/E Ratio 2027 * | 19.8x |
|---|---|---|---|---|---|
| Enterprise Value | 30TCr 26TCr 24TCr 22TCr 42TCr 28,50200Cr 43TCr 2,81800Cr 1,09900Cr 13,87300Cr 1,12500Cr 1,10100Cr 48,03500Cr | EV / Sales 2026 * |
4.74x | EV / Sales 2027 * | 4.36x |
| Free-Float |
96.63% | Yield 2026 * |
1.85% | Yield 2027 * | 1.95% |
Last Transcript: AstraZeneca PLC
| 1 day | -1.94% | ||
| Current month | +92.68% | ||
| 6 months | +95.23% | ||
| Current year | +94.44% |
| Current year | 89.04 |  | 182.7 |
| 1 year | 68.62 | | 182.7 |
| 3 years | 60.47 | | 182.7 |
| 5 years | 52.65 | | 182.7 |
| 10 years | 25.55 | | 182.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 66 | 01/10/2012 |
Aradhana Sarin
DFI | Director of Finance/CFO | 52 | 01/08/2021 |
Pam Cheng
COO | Chief Operating Officer | 55 | 01/06/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 06/04/1999 | |
Pascal Soriot
BRD | Director/Board Member | 66 | 01/10/2012 |
Philip Broadley
BRD | Director/Board Member | 65 | 27/04/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.94% | -3.87% | - | - | 28TCr | |
| -2.41% | +0.14% | +39.53% | +154.43% | 1,03500Cr | |
| +1.07% | +3.48% | +53.75% | +50.64% | 57TCr | |
| +1.32% | +0.22% | +18.35% | +65.35% | 40TCr | |
| +0.77% | 0.00% | +19.99% | +16.80% | 32TCr | |
| -1.42% | -1.44% | +45.50% | +8.37% | 30TCr | |
| +0.44% | +3.48% | +24.48% | +34.39% | 28TCr | |
| +1.66% | +1.20% | -44.67% | -47.49% | 19TCr | |
| +0.32% | +1.61% | +19.48% | +63.42% | 19TCr | |
| -0.22% | -2.76% | +12.08% | +61.30% | 16TCr | |
| Average | -0.39% | +0.97% | +20.94% | +45.24% | 38.3TCr | |
| Weighted average by Cap. | -0.88% | +1.15% | +29.85% | +71.05% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 6.33TCr 5.47TCr 5.04TCr 4.72TCr 8.84TCr 6,01900Cr 8.98TCr 60TCr 23TCr 2,93000Cr 24TCr 23TCr 10,14400Cr | 6.72TCr 5.8TCr 5.34TCr 5TCr 9.38TCr 6,38300Cr 9.52TCr 63TCr 25TCr 3,10700Cr 25TCr 25TCr 10,75800Cr |
| Net income | 1.24TCr 1.07TCr 989.26Cr 925.99Cr 1.74TCr 1,18100Cr 1.76TCr 12TCr 4.55TCr 58TCr 4.66TCr 4.57TCr 1,99100Cr | 1.41TCr 1.22TCr 1.12TCr 1.05TCr 1.97TCr 1,33900Cr 2TCr 13TCr 5.16TCr 65TCr 5.29TCr 5.17TCr 2,25600Cr |
| Net Debt | 1.96TCr 1.69TCr 1.56TCr 1.46TCr 2.74TCr 1,86300Cr 2.78TCr 18TCr 7.18TCr 91TCr 7.35TCr 7.2TCr 3,13900Cr | 1.27TCr 1.09TCr 1.01TCr 943.74Cr 1.77TCr 1,20400Cr 1.8TCr 12TCr 4.64TCr 59TCr 4.75TCr 4.65TCr 2,02900Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/26/12 | 178.75 $ | -1.94% | 23,94,262 |
| 11/26/11 | 182.28 $ | +1.86% | 17,49,433 |
| 10/26/10 | 178.96 $ | -2.44% | 21,29,693 |
| 09/26/09 | 183.43 $ | +1.04% | 19,63,806 |
| 08/26/08 | 181.55 $ | -2.37% | 20,40,150 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AZN Stock
- AZN Stock
Select your edition
All financial news and data tailored to specific country editions
